Abilify Tablet/Abilify Discmelt Overdosage

MedDRA terminology has been used to classify the adverse reactions.
In clinical trials and in postmarketing experience, adverse reactions of deliberate or accidental overdosage with oral Aripiprazole (Abilify) have been reported worldwide. These include overdoses with oral Aripiprazole (Abilify) alone and in combination with other substances. No fatality was reported with Aripiprazole (Abilify) alone. The largest known dose with a known outcome involved acute ingestion of 1260 mg of oral Aripiprazole (Abilify) (42 times the maximum recommended daily dose) by a patient who fully recovered. Deliberate or accidental overdosage was also reported in children (age 12 and younger) involving oral Aripiprazole (Abilify) ingestions up to 195 mg with no fatalities.
Common adverse reactions (reported in at least 5% of all overdose cases) reported with oral Aripiprazole (Abilify) overdosage (alone or in combination with other substances) include vomiting, somnolence, and tremor. Other clinically important signs and symptoms observed in one or more patients with Aripiprazole (Abilify) overdoses (alone or with other substances) include acidosis, aggression, aspartate aminotransferase increased, atrial fibrillation, bradycardia, coma, confusional state, convulsion, blood creatine phosphokinase increased, depressed level of consciousness, hypertension, hypokalemia, hypotension, lethargy, loss of consciousness, QRS complex prolonged, QT prolonged, pneumonia aspiration, respiratory arrest, status epilepticus, and tachycardia.
Management of Overdosage: No specific information is available on the treatment of overdose with Aripiprazole (Abilify). An electrocardiogram should be obtained in case of overdosage and if QT interval prolongation is present, cardiac monitoring should be instituted. Otherwise, management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. Close medical supervision and monitoring should continue until the patient recovers.
Charcoal: In the event of an overdose of Aripiprazole (Abilify), an early charcoal administration may be useful in partially preventing the absorption of aripiprazole. Administration of 50 g of activated charcoal, one hour after a single 15 mg oral dose of Aripiprazole (Abilify), decreased the mean AUC and Cmax of aripiprazole by 50%.
Hemodialysis: Although there is no information on the effect of hemodialysis in treating an overdose with Aripiprazole (Abilify), hemodialysis is unlikely to be useful in overdose management since aripiprazole is highly bound to plasma proteins.